Ironwood surges after Q3 beat; raised outlook for AbbVie-partnered Linzess

[$10 Banknote Stacking, Green Up Arrow Rise]
spawns

Shares of Ironwood Pharmaceuticals (IRWD [https://seekingalpha.com/symbol/IRWD]) climbed ~34% on Monday after the company well exceeded Street forecasts with its Q3 2025 financials and hiked its full-year guidance, citing growth prospects for Linzess, a bowel disease therapy it markets with AbbVie (ABBV [https://seekingalpha.com/symbol/ABBV]).

Boston, Massachusetts-based Ironwood (IRWD [https://seekingalpha.com/symbol/IRWD]) recorded $0.24 of non-GAAP earnings per share on $122.1M of revenue, beating the consensus by $0.12 and $46.4M, respectively, compared to $0.02 and $91.6M in the prior-year period. [https://seekingalpha.com/news/4519232-ironwood-pharmaceuticals-non-gaap-eps-of-0_24-beats-by-0_12-revenue-of-122_06m-beats-by]

The company attributed the ~33% YoY growth to rising net profits from U.S. sales of Linzess, which AbbVie (ABBV [https://seekingalpha.com/symbol/ABBV]) recorded as $315M in October, indicating ~40% YoY growth. [https://seekingalpha.com/news/4512592-ironwood-surges-28-percent-beneficiary-partner-abbvie-linzess-q3-sales]

“LINZESS delivered a strong third-quarter performance, driven by accelerated double-digit prescription demand growth combined with improved net pricing, which prompted us to raise our full-year 2025 financial guidance,” CEO Tom McCourt remarked.

The company raised its full-year outlook for U.S. Linzess net sales to $860M - $890M and total revenue guidance to $290M - $310M from $800M - $850M and $260M - $290M, respectively. [https://seekingalpha.com/pr/20300156-ironwood-pharmaceuticals-reports-strong-third-quarter-2025-results-raises-full-year-2025]

MORE ON IRONWOOD PHARMACEUTICALS, ABBVIE

* Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer [https://seekingalpha.com/article/4840843-healthcare-q3-dividend-roundup-i-prefer-abbvie-over-pfizer]
* AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript [https://seekingalpha.com/article/4836381-abbvie-inc-abbv-q3-2025-earnings-call-transcript]
* AbbVie: Why Q3 Confirms Its Immunology Dominance [https://seekingalpha.com/article/4836301-abbvie-why-q3-confirms-its-immunology-dominance]
* Ironwood wins FDA label expansion for bowel disease drug developed with AbbVie [https://seekingalpha.com/news/4516040-ironwood-wins-new-fda-nod-for-abbvie-partnered-bowel-drug]
* Earnings Scorecard: 24 out of 25 healthcare firms deliver EPS wins this week [https://seekingalpha.com/news/4512590-earnings-scorecard-24-out-of-25-healthcare-firms-deliver-eps-wins-this-week]